Aim: The assessment of the metabolic syndrome prevalence, as defined by the American Heart Association/The US National Cholesterol Education Program Adult Treatment Panel, (AHA/NCEP III updated), has been made in 68 polyexperimented HIV infected patients that received antiretroviral therapy over 24 months and who have a favorable viroimunologic response (undetectable plasmatic viral load).
Materials and methods: this cross-sectional analytical study has been carried out on a cohort of 68 patients clinically and paraclinically monitored at the HIV/AIDS Department.
Results: The response to antiretroviral therapy clinically and paraclinically evaluated after two years from the initiation of the novel HAART scheme has been favourable in all the 68 patients. Only 4 (0.58%) of the patients fulfill the criteria of the metabolic sindrome definition. The statistical analysis does not indicate an increase in the risk of the metabolic syndrome development in these polyexperimented patients, where the clinical symptoms connected with the lipodistrophic syndrome with lipoatrophy are preponderent, associated with different types of antiretroviral drugs.
Conclusions: The metabolic syndrome criteria are not applicable in the case of HIV infected patients (infected in the first year of life), polyexperimented at HAART therapy with favourable viroimmunologic response.